Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Successful use of etanercept for the treatment of Reiter's syndrome: a case report and review of the literature.

Literature DB >> 21785961

Successful use of etanercept for the treatment of Reiter's syndrome: a case report and review of the literature.

Abstract

The treatment of severe and refractory cases of reactive arthritis is not well defined. There is a limited data about the use of tumor necrosis factor-α (TNF-α) blockers in reactive arthritis. Herein is a description of a patient with severe case of Chlamydia trachomatis-related reactive arthritis that was refractory to nonsteroidal anti-inflammatory drugs, sulfasalazine, prednisone, and methotrexate and was successfully treated with etanercept.

Entities: Chemical

Mesh：

Substances：

Year: 2011 PMID： 21785961 DOI： 10.1007/s00296-011-2000-1

Source DB: PubMed Journal: Rheumatol Int ISSN： 0172-8172 Impact factor: 3.580

20 in total

Review 1. TNF involvement and anti-TNF therapy of reactive and unclassified arthritis.

Authors: R Meador; E Hsia; T Kitumnuaypong; H R Schumacher
Journal: Clin Exp Rheumatol Date: 2002 Nov-Dec Impact factor: 4.473

2. Alpha beta but not gamma delta T cell clones in synovial fluids of patients with reactive arthritis show active transcription of tumour necrosis factor alpha and interferon gamma.

Authors: M Rihl; J Gu; D Baeten; E Märker-Hermann; J C Goodall; J S H Gaston; J G Kuipers; H Zeidler; D T Y Yu
Journal: Ann Rheum Dis Date: 2004-12 Impact factor: 19.103

3. Infliximab for reactive arthritis secondary to Chlamydia trachomatis infection.

Authors: Marcelo Derbli Schafranski
Journal: Rheumatol Int Date: 2009-05-23 Impact factor: 2.631

Review 4. On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999.

Authors: J Braun; G Kingsley; D van der Heijde; J Sieper
Journal: J Rheumatol Date: 2000-09 Impact factor: 4.666

5. Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial.

Authors: Stephanie D Flagg; Robert Meador; Elizabeth Hsia; Tasanee Kitumnuaypong; H Ralph Schumacher
Journal: Arthritis Rheum Date: 2005-08-15

Successful use of etanercept for the treatment of Reiter's syndrome: a case report and review of the literature.

Review 1. TNF involvement and anti-TNF therapy of reactive and unclassified arthritis.

2. Alpha beta but not gamma delta T cell clones in synovial fluids of patients with reactive arthritis show active transcription of tumour necrosis factor alpha and interferon gamma.

3. Infliximab for reactive arthritis secondary to Chlamydia trachomatis infection.

Review 4. On the difficulties of establishing a consensus on the definition of and diagnostic investigations for reactive arthritis. Results and discussion of a questionnaire prepared for the 4th International Workshop on Reactive Arthritis, Berlin, Germany, July 3-6, 1999.

5. Decreased pain and synovial inflammation after etanercept therapy in patients with reactive and undifferentiated arthritis: an open-label trial.

6. Arthritis associated with Yersinia enterocolitica infection.

7. Effect of cytokines on invasion and survival of Yersinia in primary human fibroblasts.

8. Limited effect of sulphasalazine treatment in reactive arthritis. A randomised double blind placebo controlled trial.

9. Predictive factors for the longterm outcome of spondyloarthropathies.

10. Infliximab in the treatment of an HIV positive patient with Reiter's syndrome.

1. Use of biologic agents in ocular manifestations of rheumatic disease.

Review 2. Treatment of reactive arthritis with biological agents: a review.

Review 3. The role of intracellular organisms in the pathogenesis of inflammatory arthritis.